<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001536368</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001672619</issuerCik>
      <issuerName>Enliven Therapeutics, Inc.</issuerName>
      <secFileNumber>001-39247</secFileNumber>
      <issuerAddress>
        <com:street1>6200 LOOKOUT ROAD</com:street1>
        <com:city>BOULDER</com:city>
        <com:stateOrCountry>CO</com:stateOrCountry>
        <com:zipCode>80301</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>720-647-8519</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Kunkel Lori Anne</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Board Member</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Jefferies LLC</name>
        <address>
          <com:street1>520 Madison Ave</com:street1>
          <com:street2>4th Fl</com:street2>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10022</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>20000</noOfUnitsSold>
      <aggregateMarketValue>709800.00</aggregateMarketValue>
      <noOfUnitsOutstanding>61000000</noOfUnitsOutstanding>
      <approxSaleDate>06/05/2026</approxSaleDate>
      <securitiesExchangeName>Nasdaq</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <acquiredDate>03/12/2020</acquiredDate>
      <natureOfAcquisitionTransaction>Pre-IPO Shares</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Enliven Therapeutics, Inc</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>20000</amountOfSecuritiesAcquired>
      <paymentDate>03/12/2020</paymentDate>
      <natureOfPayment>N/A</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 03/06/2026, and all representations regarding material non-public information were made as of the adoption of the plan.</remarks>
    <noticeSignature>
      <noticeDate>06/05/2026</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>03/06/2026</planAdoptionDate>
      </planAdoptionDates>
      <signature>Lori Kunkel</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
